Samantha Cassar1,2, Helena J Teede2,3, Cheryce L Harrison2, Anju E Joham2,3, Lisa J Moran2,4, Nigel K Stepto1,2. 1. Institute of Sport, Exercise and Active Living, Victoria University, Melbourne, Vic., Australia. 2. Monash Centre for Health Research and Implementation, School of Public Health and Preventive Medicine, Monash University, Melbourne, Vic., Australia. 3. Diabetes and Vascular Medicine Unit, Monash Health, Melbourne, Vic., Australia. 4. The Robinson Research Institute, Discipline of Obstetrics and Gynaecology, University of Adelaide, Adelaide, SA, Australia.
Abstract
OBJECTIVE: Polycystic ovary syndrome (PCOS) is a common endocrine disorder associated with metabolic complications. Metabolic biomarkers with roles in obesity, glycaemic control and lipid metabolism are potentially relevant in PCOS. The aim was to investigate metabolic biomarkers in lean and overweight women with and without PCOS and to determine whether any biomarker was able to predict insulin resistance in PCOS. DESIGN: Cross-sectional study. PATIENTS: Eighty-four women (22 overweight and 22 lean women with PCOS, 18 overweight and 22 lean women without PCOS) were recruited from the community and categorized based on PCOS and BMI status. MEASUREMENTS: Primary outcomes were metabolic biomarkers [ghrelin, resistin, visfatin, glucagon-like peptide-1 (GLP-1), leptin, plasminogen activator inhibitor -1 (PAI-1), glucose-dependent insulinotropic polypeptide (GIP) and C-Peptide] measured using the Bio-Plex Pro Diabetes assay and insulin sensitivity as assessed by glucose infusion rate on euglycaemic-hyperinsulinaemic clamp. RESULTS: The biomarkers C-peptide, leptin, ghrelin and visfatin were different between overweight and lean women, irrespective of PCOS status. The concentration of circulating biomarkers did not differ between women with PCOS diagnosed by the Rotterdam criteria or National Institute of Health criteria. PAI-1 was the only biomarker that significantly predicted insulin resistance in both control women (P = 0.04) and women with PCOS (P = 0.01). CONCLUSIONS: Biomarkers associated with metabolic diseases appear more strongly associated with obesity rather than PCOS status. PAI-1 may also be a novel independent biomarker and predictor of insulin resistance in women with and without PCOS.
OBJECTIVE:Polycystic ovary syndrome (PCOS) is a common endocrine disorder associated with metabolic complications. Metabolic biomarkers with roles in obesity, glycaemic control and lipid metabolism are potentially relevant in PCOS. The aim was to investigate metabolic biomarkers in lean and overweight women with and without PCOS and to determine whether any biomarker was able to predict insulin resistance in PCOS. DESIGN: Cross-sectional study. PATIENTS: Eighty-four women (22 overweight and 22 lean women with PCOS, 18 overweight and 22 lean women without PCOS) were recruited from the community and categorized based on PCOS and BMI status. MEASUREMENTS: Primary outcomes were metabolic biomarkers [ghrelin, resistin, visfatin, glucagon-like peptide-1 (GLP-1), leptin, plasminogen activator inhibitor -1 (PAI-1), glucose-dependent insulinotropic polypeptide (GIP) and C-Peptide] measured using the Bio-Plex Pro Diabetes assay and insulin sensitivity as assessed by glucose infusion rate on euglycaemic-hyperinsulinaemic clamp. RESULTS: The biomarkers C-peptide, leptin, ghrelin and visfatin were different between overweight and lean women, irrespective of PCOS status. The concentration of circulating biomarkers did not differ between women with PCOS diagnosed by the Rotterdam criteria or National Institute of Health criteria. PAI-1 was the only biomarker that significantly predicted insulin resistance in both control women (P = 0.04) and women with PCOS (P = 0.01). CONCLUSIONS: Biomarkers associated with metabolic diseases appear more strongly associated with obesity rather than PCOS status. PAI-1 may also be a novel independent biomarker and predictor of insulin resistance in women with and without PCOS.
Authors: Nadine M P Daan; Maria P H Koster; Marlieke A de Wilde; Gerdien W Dalmeijer; Annemieke M V Evelein; Bart C J M Fauser; Wilco de Jager Journal: PLoS One Date: 2016-11-02 Impact factor: 3.240
Authors: Balachandran Kumarendran; Michael W O'Reilly; Konstantinos N Manolopoulos; Konstantinos A Toulis; Krishna M Gokhale; Alice J Sitch; Chandrika N Wijeyaratne; Arri Coomarasamy; Wiebke Arlt; Krishnarajah Nirantharakumar Journal: PLoS Med Date: 2018-03-28 Impact factor: 11.069
Authors: Simona Ferjan; Mojca Jensterle; Tjasa Oblak; Irena Prodan Zitnik; Janja Marc; Katja Goricar; Vita Dolzan; Andrej Janez Journal: J Int Med Res Date: 2019-08-23 Impact factor: 1.671
Authors: Sebastiao Freitas de Medeiros; Laura Camila Antunes Angelo; Matheus Antonio Souto de Medeiros; Camila Regis Banhara; Bruna Barcelo Barbosa; Marcia Marly Winck Yamamoto Journal: J Clin Med Res Date: 2018-01-26
Authors: M Ángeles Martínez-García; Samuel Moncayo; María Insenser; Francisco Álvarez-Blasco; Manuel Luque-Ramírez; Héctor F Escobar-Morreale Journal: Nutrients Date: 2019-10-24 Impact factor: 5.717